acamprosate calcium

FDA Drug Profile — acamprosate calcium

acamprosate calcium is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including acamprosate calcium. Available dosage form: tablet, delayed release.

Drug Details

Generic Name
acamprosate calcium
Brand Names
acamprosate calcium
Application Number
ANDA205995
Sponsor
Zydus Pharmaceuticals (USA) Inc.
NDC Codes
3
Dosage Forms
TABLET, DELAYED RELEASE
Routes
ORAL
Active Ingredients
ACAMPROSATE CALCIUM

Indications and Usage

1 INDICATIONS AND USAGE Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium delayed-release tablets treatment. The efficacy of acamprosate calcium delayed-release tablets in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. • Acamprosate calcium delayed-release tablets are indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation ( 1 , 14 ). • Treatment with acamprosate calcium delayed-release tablets should be part of a comprehensive management program that includes psychosocial support ( 1 ).